KALA BIO, Inc. (KALA) stock
KALANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.14−0.02 (-13.79%)
Close on Nov 13, 2026Market cap $2.68MP/E –Yield –
Kala Bio profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Kala Bio's profit margin for the twelve months ending Dec 31, 2022 was -1151.6%. For fiscal 2022 it was -1151.6%, against -1268.7% the year before. The highest annual figure on record is -1151.6% in fiscal 2022.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | -1151.6% | +117.1 |
| FY2021 | Dec 31, 2021 | -1268.7% | +371.1 |
| FY2020 | Dec 31, 2020 | -1639.8% | −86.6 |
| FY2019 | Dec 31, 2019 | -1553.3% | +35517.8 |
| FY2015 | Dec 31, 2015 | -37071.1% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2022 | Sep 30, 2022 | 6922.1% | +7839.2 |
| Q2 FY2022 | Jun 30, 2022 | -1338.6% | −142.4 |
| Q1 FY2022 | Mar 31, 2022 | -2400.9% | −1469.8 |
| Q4 FY2021 | Dec 31, 2021 | -2562.9% | −1172.8 |
| Q3 FY2021 | Sep 30, 2021 | -917.1% | +341.8 |
| Q2 FY2021 | Jun 30, 2021 | -1196.3% | +1602.3 |
| Q1 FY2021 | Mar 31, 2021 | -931.2% | +1118.8 |
| Q4 FY2020 | Dec 31, 2020 | -1390.2% | +470.7 |
| Q3 FY2020 | Sep 30, 2020 | -1258.9% | +338.3 |
| Q2 FY2020 | Jun 30, 2020 | -2798.6% | −1640.3 |
| Q1 FY2020 | Mar 31, 2020 | -2050.0% | −218.2 |
| Q4 FY2019 | Dec 31, 2019 | -1860.8% | – |
| Q3 FY2019 | Sep 30, 2019 | -1597.2% | – |
| Q2 FY2019 | Jun 30, 2019 | -1158.2% | – |
| Q1 FY2019 | Mar 31, 2019 | -1831.7% | – |
See a number that looks wrong?